Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials.

Nreu B, Dicembrini I, Tinti F, Sesti G, Mannucci E, Monami M

Nutrition, metabolism, and cardiovascular diseases : NMCD25 Mar 2020Cited by 68 (Europe PMC)

PMID32448716DOI10.1016/j.numecd.2020.03.013PepBankPUB-32448716

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (a class that includes liraglutide) significantly reduced MACE.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class, which includes liraglutide, reduced major heart events when pooled.
Peptide
Liraglutide
Outcome
DecreaseMajor cardiovascular events (MACE)
Study
n = 63,134
Comparator
Placebo or non-GLP-1 receptor agonist drugs
Outcome group
Cardiovascular events · Cardiovascular
Measurements
MH-OR
0.87 OR
pooled GLP-1 RAs, MACE
Source sentences
Summary
A significant reduction of MACE (MH-OR 0.87 [0.83, 0.92])
2 context sentences(design, population, supporting numbers)
Summary · context
A Medline search for GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, or semaglutide) was performed, collecting all randomized clinical trials with a duration ≥52 weeks, enrolling patients with type 2 diabetes, and comparing a GLP-1 receptor agonist with place…
Summary · context
We included 43 trials, enrolling 63,134 patients.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3244871601
02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (a class that includes liraglutide) significantly reduced all-cause mortality.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class, which includes liraglutide, reduced deaths from any cause when pooled.
Peptide
Liraglutide
Outcome
DecreaseAll-cause mortality
Study
n = 63,134
Comparator
Placebo or non-GLP-1 receptor agonist drugs
Outcome group
Mortality · Cardiovascular
Measurements
MH-OR
0.89 OR
pooled GLP-1 RAs, all-cause mortality
Source sentences
Summary
all-cause mortality (MH-OR 0.89 [0.83, 0.96])
2 context sentences(design, population, supporting numbers)
Summary · context
A Medline search for GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, or semaglutide) was performed, collecting all randomized clinical trials with a duration ≥52 weeks, enrolling patients with type 2 diabetes, and comparing a GLP-1 receptor agonist with place…
Summary · context
We included 43 trials, enrolling 63,134 patients.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3244871602
03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (a class that includes liraglutide) showed a nonsignificant trend toward fewer heart failure events.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class, which includes liraglutide, showed only a non-significant trend toward less heart failure.
Peptide
Liraglutide
Outcome
No significant changeHeart failure
Study
n = 63,134
Comparator
Placebo or non-GLP-1 receptor agonist drugs
Outcome group
Cardiovascular events · Cardiovascular
Measurements
MH-OR
0.93 OR
pooled GLP-1 RAs, heart failure
Source sentences
Summary
a nonstatistical trend toward reduction of heart failure (MH-OR 0.93 [0.85, 1.01])
2 context sentences(design, population, supporting numbers)
Summary · context
A Medline search for GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, or semaglutide) was performed, collecting all randomized clinical trials with a duration ≥52 weeks, enrolling patients with type 2 diabetes, and comparing a GLP-1 receptor agonist with place…
Summary · context
We included 43 trials, enrolling 63,134 patients.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3244871603
04HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (a class that includes liraglutide) did not increase the risk of atrial fibrillation.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class, which includes liraglutide, did not raise the risk of atrial fibrillation.
Peptide
Liraglutide
Outcome
No significant changeAtrial fibrillation
Study
n = 63,134
Comparator
Placebo or non-GLP-1 receptor agonist drugs
Outcome group
Cardiovascular events · Cardiovascular
Measurements
MH-OR
0.94 OR
pooled GLP-1 RAs, atrial fibrillation
Source sentences
Summary
GLP1-RA did not increase the risk of atrial fibrillation (MH-OR 0.94 [0.84, 1.04]).
2 context sentences(design, population, supporting numbers)
Summary · context
A Medline search for GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, or semaglutide) was performed, collecting all randomized clinical trials with a duration ≥52 weeks, enrolling patients with type 2 diabetes, and comparing a GLP-1 receptor agonist with place…
Summary · context
We included 43 trials, enrolling 63,134 patients.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3244871604
05HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (a class that includes semaglutide) significantly reduced MACE.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class, which includes semaglutide, reduced major heart events when pooled.
Peptide
Semaglutide
Outcome
DecreaseMajor cardiovascular events (MACE)
Study
n = 63,134
Comparator
Placebo or non-GLP-1 receptor agonist drugs
Outcome group
Cardiovascular events · Cardiovascular
Measurements
MH-OR
0.87 OR
pooled GLP-1 RAs, MACE
Source sentences
Summary
A significant reduction of MACE (MH-OR 0.87 [0.83, 0.92])
2 context sentences(design, population, supporting numbers)
Summary · context
A Medline search for GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, or semaglutide) was performed, collecting all randomized clinical trials with a duration ≥52 weeks, enrolling patients with type 2 diabetes, and comparing a GLP-1 receptor agonist with place…
Summary · context
We included 43 trials, enrolling 63,134 patients.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3244871605
06HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (a class that includes semaglutide) significantly reduced all-cause mortality.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class, which includes semaglutide, reduced deaths from any cause when pooled.
Peptide
Semaglutide
Outcome
DecreaseAll-cause mortality
Study
n = 63,134
Comparator
Placebo or non-GLP-1 receptor agonist drugs
Outcome group
Mortality · Cardiovascular
Measurements
MH-OR
0.89 OR
pooled GLP-1 RAs, all-cause mortality
Source sentences
Summary
all-cause mortality (MH-OR 0.89 [0.83, 0.96])
2 context sentences(design, population, supporting numbers)
Summary · context
A Medline search for GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, or semaglutide) was performed, collecting all randomized clinical trials with a duration ≥52 weeks, enrolling patients with type 2 diabetes, and comparing a GLP-1 receptor agonist with place…
Summary · context
We included 43 trials, enrolling 63,134 patients.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3244871606
07HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (a class that includes semaglutide) showed a nonsignificant trend toward fewer heart failure events.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class, which includes semaglutide, showed only a non-significant trend toward less heart failure.
Peptide
Semaglutide
Outcome
No significant changeHeart failure
Study
n = 63,134
Comparator
Placebo or non-GLP-1 receptor agonist drugs
Outcome group
Cardiovascular events · Cardiovascular
Measurements
MH-OR
0.93 OR
pooled GLP-1 RAs, heart failure
Source sentences
Summary
a nonstatistical trend toward reduction of heart failure (MH-OR 0.93 [0.85, 1.01])
2 context sentences(design, population, supporting numbers)
Summary · context
A Medline search for GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, or semaglutide) was performed, collecting all randomized clinical trials with a duration ≥52 weeks, enrolling patients with type 2 diabetes, and comparing a GLP-1 receptor agonist with place…
Summary · context
We included 43 trials, enrolling 63,134 patients.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3244871607
08HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (a class that includes semaglutide) did not increase the risk of atrial fibrillation.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class, which includes semaglutide, did not raise the risk of atrial fibrillation.
Peptide
Semaglutide
Outcome
No significant changeAtrial fibrillation
Study
n = 63,134
Comparator
Placebo or non-GLP-1 receptor agonist drugs
Outcome group
Cardiovascular events · Cardiovascular
Measurements
MH-OR
0.94 OR
pooled GLP-1 RAs, atrial fibrillation
Source sentences
Summary
GLP1-RA did not increase the risk of atrial fibrillation (MH-OR 0.94 [0.84, 1.04]).
2 context sentences(design, population, supporting numbers)
Summary · context
A Medline search for GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, or semaglutide) was performed, collecting all randomized clinical trials with a duration ≥52 weeks, enrolling patients with type 2 diabetes, and comparing a GLP-1 receptor agonist with place…
Summary · context
We included 43 trials, enrolling 63,134 patients.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3244871608

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 3
12 Oct 2026, 11:11 UTC
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials.

Summary

Results from this study8

Studies that did not test the peptide alone8

Version history

Subjects

Publication types

MeSH terms

Keywords